For x =20.9 and 29.5, the stress T dependencies of the saturation magnetostrictions were found to be 0.136 X 10(-6)T MPa-1 and 0.281 X 10(-6)T MPa-1, respectively. Values of the third order elastic constants, c(3)’s, calculated from these values agree both in sign and magnitude with those obtained from stress dependent measurements of Young’s moduli and Poisson’s ratios. In sum, we conclude that the Fe100-xGax magnetostriction for this website 0<x<30 can be attributed to a simple homogenous single domain magnetoelastic mechanism. (C) 2009 American Institute of Physics. [DOI: 10.1063/1.3058685]“
“Metastatic breast cancer is currently incurable and the goals of therapy focus on prolonging survival and
maintaining quality of life by controlling symptoms and minimizing toxicity. Treatments for metastatic breast cancer include chemotherapeutic agents from various classes, such as taxanes, vinca alkaloids, anthracyclines and antimetabolites. This review Selleckchem YM155 provides an overview
of chemotherapeutic agents for the treatment of metastatic breast cancer patients previously treated with anthracyclines and taxanes, focusing on a clinical evaluation of eribulin, the most recently approved agent for the treatment of metastatic breast cancer. Eribulin is a synthetic derivative of halichondrin B, a tumour growth inhibitor found in marine sponges, which prevents microtubule growth and sequesters the tubulin molecules into unusual aggregates, initiating apoptosis. Studies of eribulin have shown that the drug is effective in the treatment of previously treated metastatic breast cancer, and has an acceptable toxicity profile. Importantly, EPZ5676 manufacturer in the phase III EMBRACE study, eribulin treatment resulted in a survival advantage, a difficult endpoint to achieve
with a single chemotherapeutic agent. An additional phase III study showed that eribulin has similar efficacy to capecitabine in women treated with no more than three prior therapies. Furthermore, pre-specified exploratory analyses suggest that particular patient subgroups may have greater therapeutic benefit with eribulin and may warrant further study to explore the potential mechanisms.”
“Objectives: The aim of this study is to investigate the role of social support and coping strategies in enhancing post-traumatic growth (PTG) in cancer patients. The study focused on both avoidance and approaching coping and on four distinct types of social support: (a) perceived availability, (b) actual received, (c) satisfaction with received support, and (d) the competence of caregiver to satisfy the patient’s basic psychological needs of autonomy, competence, and relatedness.
Methods: A longitudinal study was conducted with a group of 41 cancer patients currently in the treatment and management phase of their illness. Data were collected by means of a written questionnaire, at two time points (T1 and T2) that were 6 months apart.